Key Studies Influencing My Practice Following IAS 2021—Audio Recap
Listen to expert insights from Babafemi Taiwo, MBBS, on updates from IAS 2021, including new data on COVID-19 and HIV, 2-drug ART, long-acting injectable ART, investigational agents, and new therapies for multidrug-resistant tuberculosis.
Decera Clinical Education Infectious Disease Podcast
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Babafemi Taiwo, MBBS, discusses new HIV data from IAS 2021, including:
- WHO Global Clinical Platform: COVID-19 outcomes in PWH
- 2-drug regimen of DTG/3TC: efficacy, metabolic outcomes (TANGO)
- Investigational antiretroviral use
- CAB LA + RPV LA in treatment-naive PWH (FLAIR)
- Investigational antiretroviral agents
- LEN (CAPELLA, CALIBRATE)
- ISL (P011, P016)
- Alternative BPaL dosing in treatment of drug-resistant TB (ZeNix)
Babafemi Taiwo, MBBS
Gene Stollerman Professor of Medicine
Chief, Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Content based on a CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP.; Merck Sharp & Dohme Corp; and ViiV Healthcare.
Follow along with an expanded slideset at:
https://bit.ly/3syWD5T
Link to full program:
https://bit.ly/3z8SBnC
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.